|
|
|
|
| LEADER |
01864nam a2200325 u 4500 |
| 001 |
EB001865395 |
| 003 |
EBX01000000000000001029475 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
190504 r ||| eng |
| 245 |
0 |
0 |
|a Pharmacoeconomic review report: Travoprost 0.003% (Izba) (Novartis Pharmaceuticals Canada Inc. on behalf of Icon Canada Inc.)
|h Elektronische Ressource
|
| 246 |
3 |
1 |
|a Pharmacoeconomic review report for Izba
|
| 246 |
3 |
1 |
|a Travoprost 0.003% (Izba) (Novartis Pharmaceuticals Canada Inc. on behalf of Icon Canada Inc.)
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c November 2017, 2017
|
| 300 |
|
|
|a 1 PDF file (18 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Ocular Hypertension / drug therapy
|
| 653 |
|
|
|a Glaucoma, Open-Angle / drug therapy
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Travoprost / economics
|
| 653 |
|
|
|a Intraocular Pressure
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 500 |
|
|
|a "Version: Final."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK535046
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a Polyquaternium-1-preserved travoprost 0.003% ophthalmic solution (Izba, travoprost 0.003% PQ) is a prostaglandin analogue (PGA) indicated for the reduction of intraocular pressure (IOP) among patients with open-angle glaucoma (OAG) or ocular hypertension. Travoprost 0.003% PQ is available as a topical ophthalmic solution with a recommended dose of one drop in the affected eye(s) per day. The manufacturer is requesting reimbursement per indication and has submitted a market price of $20.13 per 5 mL bottle
|